Studies show that gray matter atrophy correlates with disability progression and drives whole brain atrophy in MS.
AMSTERDAM—Gray matter atrophy may serve as an effective outcome measure for clinical trials in multiple sclerosis (MS), said Richard A. Rudick, MD, Vice Chair of the Neurological Institute at the Cleveland Clinic. He described the latest research on gray matter atrophy at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS).
According to Dr. Rudick, conventional MRI techniques almost entirely overlook gray matter pathology, even though 65% of the brain is composed of gray matter. “As a result, all of our focus has been on white matter, and the conventional MRI really just visualizes a small portion of the underlying pathology. [Gray matter pathology] is truly a Trojan horse in MS.”